Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 219

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 219
---
 their effect was anti-dilutive

The loss and
the weighted average number of shares used in computing basic and diluted net loss per share for the 3 months period ended March 31, 2025
and 2024, are as follows:

|                                                                                 |     |     Successor |            |     |   Predecessor |         |
|                                                                                 |     | For the three 
  months ended 
     March 31, |            |     | For the three 
  months ended 
     March 31, |         |
|                                                                                 |     |          2025 |            |     |          2024 |         |
|                                                                                 |     |     Unaudited |            |     |     Unaudited |         |
| Numerator:                                                                      |     |               |            |     |               |         |
| Net loss applicable to shareholders of Ordinary Share                           |     |               |        634 |     |               |     650 |
| Denominator:                                                                    |     |               |            |     |               |         |
| Shares of Ordinary Share used in computing basic and diluted net loss per share |     |               | 60,729,100 |     |               | 143,447 |
| Net loss per share of Ordinary Share, basic and diluted                         |     |               |       0.01 |     |               |    4.53 |

<div align='center'>F-41</div>

REVIUM RX.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S. dollars in thousands

NOTE 5 – SHAREHOLDERS’ EQUITY

Share-based
expenses recognized in the financial statements:

|                                     |     |     Successor |     |     |   Predecessor |     |
|                                     |     | For the three 
  months ended 
     March 31, |     |     | For the three 
  months ended 
     March 31, |     |
|                                     |     |          2025 |     |     |          2024 |     |
|                                     |     |     Unaudited |     |     |     Unaudited |     |
| Research and development expenses   |     |               |  93 |     |               | 291 |
| General and administrative expenses |     |               | 247 |     |               |   - |
| Total                               |     |               | 340 |     |               | 291